(48 days)
Not Found
Not Found
No
The description details a standard enzyme immunoassay (EIA) kit, which is a biochemical method for measuring substances. There is no mention of AI, ML, or any computational analysis beyond basic spectrophotometry and linear regression for performance comparison.
No
The device is an in vitro diagnostic (IVD) assay designed to measure T4 levels in serum for the diagnosis and treatment of thyroid disease. It does not directly treat or prevent disease, but rather provides information for diagnostic purposes.
Yes
The "Intended Use / Indications for Use" section explicitly states, "This assay is intended for in vitro diagnostic use in the diagnosis and treatment of thyroid disease."
No
The device description clearly describes a physical kit with reagents, microtitration wells, and a process involving washing, decanting, and analysis in a spectrophotometer. This indicates a hardware-based in vitro diagnostic device, not a software-only device.
Yes, this device is an IVD (In Vitro Diagnostic).
The "Intended Use / Indications for Use" section explicitly states: "This assay is intended for in vitro diagnostic use in the diagnosis and treatment of thyroid disease."
This statement directly identifies the device as being used outside of the body (in vitro) for diagnostic purposes.
N/A
Intended Use / Indications for Use
The DSL ACTIVE™ T4 EIA assay is intended for the quantitative determination of T4 in human serum. The measurement of T4 is used in the diagnosis and treatment of thyroid disease.
The DSL-10-3200 T4 Enzymeimmunoassay (EIA) Kit provides materials for the quantitative measurement of T4 in serum. This assay is intended for in vitro diagnostic use in the diagnosis and treatment of thyroid disease.
Product codes
KLI
Device Description
The DSL ACTIVE™ T4 EIA kit was developed for the quantitative measurement of T4 in human serum. The EIA format is a competitive binding protein assay. Enzyme-labeled T4 competes with un-labeled T4 in the serum sample for binding sites with the Anti-T4 antibody in microtitration wells. Separation of free from bound T4 is achieved by washing and decanting the microtiter plates after incubation. The resultant is analyzed in a spectrophotometer for absorbance. The amount of enzyme-labeled T4 bound to the antibody is inversely proportional to tne concentration of the T4 present in the sample.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
To demonstrate substantial equivalence between the two assays, patient samples (n = 59) were collected and assayed using both methods. Samples were chosen based on expected T4 levels so that samples with low, intermediate and high levels would be evaluated. Linear regression analysis of the results obtained for the comparison gave the equation Y =0.72(X) -0.24 with a correlation coefficient of (r) = 0.96.
Key Metrics
Y =0.72(X) -0.24 with a correlation coefficient of (r) = 0.96.
Predicate Device(s)
The DSL ACTIVE™ T4 EIA is substantially equivalent to the DSL ACTIVE™ T4 RIA.
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 862.1700 Total thyroxine test system.
(a)
Identification. A total thyroxine test system is a device intended to measure total (free and protein bound) thyroxine (thyroid hormone) in serum and plasma. Measurements obtained by this device are used in the diagnosis and treatment of thyroid diseases.(b)
Classification. Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.
0
Image /page/0/Picture/0 description: The image shows a stylized logo or symbol in black against a white background. The logo appears to be a combination of two letter-like shapes. The first shape resembles a lowercase 'd' with a curved body and a vertical stroke. The second shape is similar to a lowercase 'l' with a curved base. The overall design is simple and modern.
MAY 22 1997
445 Wellington Street
Leicester LE45 5BA
Tel: 23 55 44
Fax: 25 44 55
Customer Assistance
Tel: 8002 22 00
Fax: 2813 33 95
Email: mrg@d.co
SUMMARY OF SAFETY AND EFFECTIVENESS
DSL 10-3200 ACTIVE™ T4 EIA Kit Name of Device: Enzymeimmunoassay, T4 Classification Name: Analyte Code and Name: T4 Requlatory Class: =
John Willis Submitter: Diagnostic Systems Laboratories, Inc. 445 Medical Center Boulevard Webster, Texas 77598 Phone: 281-332-9678
May 14, 1997 Date:
The DSL ACTIVE™ T4 EIA kit was developed for the quantitative measurement of T4 in human serum. The EIA format is a competitive binding protein assay. Enzyme-labeled T4 competes with un-labeled T4 in the serum sample for binding sites with the Anti-T4 antibody in microtitration wells. Separation of free from bound T4 is achieved by washing and decanting the microtiter plates after incubation. The resultant is analyzed in a spectrophotometer for absorbance. The amount of enzyme-labeled T4 bound to the antibody is inversely proportional to tne concentration of the T4 present in the sample.
The DSL ACTIVE™ T4 EIA assay is intended for the quantitative determination of T4 in human serum. The measurement of T4 is used in the diagnosis and treatment of thyroid disease.
The DSL ACTIVE™ T4 EIA is substantially equivalent to the DSL ACTIVE™ T4 RIA.
To demonstrate substantial equivalence between the two assays, patient samples (n = 59) were collected and assayed using both methods. Samples were chosen based on expected T4 levels so that samples with low, intermediate and high levels would be evaluated. Linear regression analysis of the results obtained for the comparison gave the equation Y =0.72(X) -0.24 with a correlation coefficient of (r) = 0.96.
1
Image /page/1/Picture/1 description: The image shows the logo for the Department of Health & Human Services USA. The logo is a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized image of an eagle with its wings spread, symbolizing the department's mission to protect the health of all Americans.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
MAY 22 1997
John Willis Director of Requlatory Affairs Diagnostic Systems Laboratories, Inc. 445 Medical Center Boulevard
Webster, Texas 77598
Re : K971269 DSL 10-3200 ACTIVE™ T4 EIA Kit Requlatory Class: II KLI Product Code: Dated: April 3, 1997
Received: April 4, 1997
Dear Mr. Willis:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions The general controls provisions of the Act of the Act. include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major requlations affecting your device can be found in the Code of Federal Requlations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Good Manufacturing Practice for Medical Devices: General ... (GMP) regulation (21 CFR Part 820) and that, through periodic GMP inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
2
Page 2
Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770) 488-7655.
This letter will allow you to begin marketing your device as ~ described in your 510 (k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling requlation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to
premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html".
Sincerely yours,
Steven Gutman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
3
510(k) Number (if known):
Device Name: Thyroxine (T4) EIA
Indications For Use: "
The DSL-10-3200 T4 Enzymeimmunoassay (EIA) Kit provides materials for the quantitative measurement of T4 in serum. This assay is intended for in vitro diagnostic use in the diagnosis and treatment of thyroid disease.
IPLEASE DO NOT WRITE BELOW THIS LINE. CONTINUE ON ANOTHER PAGE IF NEEDED)
| Concurrence of CDRH, Office of Device Evaluation (ODE) | |
|---|---|
| (Div. | |
| Div. | ices |
| 510(k) Numbe | K971269 |
Prescription Use
(Per 21 CFR 801.109)
્વમ
Over-The-Counter Use_